Challenges of single and multiplex biomarker validation on ‘planet Earth’ versus ‘planet Biomarkertopia’
This presentation will focus on case studies through the eyes of a biomarker scientist working before and after being transported from ‘planet Earth’ to ‘planet Biomarkertopia’ to demonstrate the processes, challenges and some of the limitations of validating biomarker assays using single and multiplexing approach. You will learn the latest trend in single and multiplex biomarker assay validation.
What will you learn?
- Latest trends in biomarker validation practices
- Challenges and limitations of using RUO kits in support of clinical trials
- How to overcome some of the challenges of biomarker validation
Who may this interest?
- Biomarker scientists and managers
- Translational medicine team leaders
- Translational procurement
- Validation scientists
- Bioanalytical scientists
Founder and Global Chief Scientific Officer
Dr. Afshin Safavi is a veteran biochemist with extensive experience establishing and leading bioanalytical teams in pharmaceutical, biotechnology, and manufacturing companies, as well as contract research organizations. He and his teams have supported the development of a broad range of therapeutics in pre-clinical and clinical trial laboratories. Prior to founding BioAgilytix, he was the Director of Ligand Binding and Immunoassay at AAIPharma. At Talecris BioTherapeutics, he led the Preclinical and Clinical Assay Development team, building on his experience as a senior scientist at Nobex Corporation, GlaxoSmithKline and IGEN International. Dr. Safavi is considered an expert in the area of immunoassays with focus on biomarkers, with a wide working knowledge of various platforms. He obtained his B.S. in Biochemistry from UCLA, his Ph.D. in Biochemistry from the University of Kentucky’s Medical School (Department of Biochemistry), and he completed a two-year postdoctoral assignment at Emory University’s Department of Pathology.
For a full list of other webinars available on Bioanalysis Zone please see here.